雷米普利片联合布美他尼注射液对慢性充血性心力衰竭患者运动耐量及血清胱抑素C、NT-proBNP水平的影响  

Effects of ramipril tablet combined with bumetanide injection on exercise tolerance, serum cystatin C and NT-proBNP in patients with chronic congestive heart failure

作　　者：李建彬 胡凤英 濮欣 LI Jian-bin;HU Feng-ying;PU Xin(Beijing Anzhen Hospital of Capital Medical University,Beijing 100029,China;Xincheng Hospital of Tianjin University,Tianjing 300480,China;Tianjin the First Central Hospital,Tianjin 300480,China)

机构地区：[1]首都医科大学附属北京安贞医院,北京市心肺血管疾病研究所,北京100029 [2]天津大学新城医院,天津300480 [3]天津市第一中心医院,天津300480

出　　处：《医药论坛杂志》2023年第1期8-12,共5页Journal of Medical Forum

摘　　要：目的 探讨雷米普利片联合布美他尼注射液对慢性充血性心力衰竭患者(CHF)运动耐量及血清胱抑素C(Cys-C)、NT-proBNP水平的影响。方法 选取2020年5月—2022年6月在首都医科大学附属北京安贞医院收治的96例CHF患者,采用简单随机分组利用随机数表法将纳入CHF患者分为观察组(n=48例)和对照组(n=48例)。对照组采用雷米普利片,观察组采用雷米普利片联合布美他尼注射液,均持续治疗2周。比较两组治疗前后CHF患者治疗疗效、心功能指标(LVESD、LVEF、LVEDD),通过6 min步行试验(6MWD)比较两组患者的运动耐量,采用MLHFQ评估治疗前后两组CHF患者的生活质量,检测两组治疗前后血清Cys-C、NT-proBNP水平,观察两组CHF患者在治疗中可能发生的不良反应。结果 治疗后,观察组CHF患者治疗总有效率为93.75%,高于对照组总有效率79.17%(P<0.05);治疗2周后,两组LVESD、LVEF、LVEDD指标均优于治疗前,且观察组各指标优于对照组(P<0.05);治疗2周后,两组CHF患者6MWD距离均较治疗前增加,且观察组6MWD距离远于对照组(P<0.05);两组MLHFQ评分均降低与对照组相比,观察组CHF患者的MLHFQ评分低于对照组,差异具有显著性;治疗后,观察组和对照组Cys-C、NT-proBNP水平均降低,且观察组低于对照组(P<0.05);观察组不良反应发生率为6.25%,与对照组(16.67%)相比无显著差异(P>0.05)。结论 雷米普利片联合布美他尼注射液治疗CHF患者治疗效果明确,可以提高运动耐量,降低血清Cys-C、NT-proBNP水平,有助于CHF患者心功能恢复。Objective To explore the effects of ramipril tablet combined with bumetanide injection on exercise tolerance, serum cystatin C(Cys-C) and N-terminal B-type pronatriuretic peptide(NT-proBNP) in patients with chronic congestive heart failure(CHF). Methods A total of 96 patients with CHF admitted to the hospital were enrolled between May 2020 and June 2022. They were divided into observation group(n=48) and control group(n=48) by simple random grouping, random number table. The control group was treated with ramipril tablets, while observation group was additionally treated with bumetanide injection. All were continuously treated for 2 weeks. The curative effect and cardiac function indexes [left ventricular end systolic diameter(LVESD), left ventricular ejection fraction(LVEF), left ventricular end diastolic diameter(LVEDD)] were compared between the two groups before and after treatment. The exercise tolerance of patients was evaluated by 6-minute walking distance(6MWD). The quality of life before and after treatment was evaluated by Minnesota Living with Heart Failure Questionnaire(MLHFQ). The levels of serum Cys-C and NT-proBNP were detected before and after treatment. The occurrence of adverse reactions during treatment in both groups was recorded. Results After treatment, total response rate of treatment in observation group was higher than that of control group(93.75% vs 79.17%)(P<0.05). After treatment, LVESD, LVEF and LVEDD in both groups were improved, which were better in observation group than that of control group(P<0.05). After 2 weeks of treatment, 6MWD in both groups was increased, which was farther in observation group than that of control group(P<0.05). After 2 weeks of treatment, MLHFQ scores in both groups decreased, which was lower in observation group than that of control group(P<0.05). After 2 weeks of treatment, levels of Cys-C and NT-proBNP in both groups decreased, which were lower in observation group than those of control group(P<0.05). There was no significant difference in incidence of

关 键 词：雷米普利片 布美他尼注射液 胱抑素C N末端B型钠尿肽原 慢性充血性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]